bims-aukdir Biomed News
on Automated knowledge discovery in diabetes research
Issue of 2026–04–26
twenty papers selected by
Mott Given



  1. Diagn Progn Res. 2026 Apr 20. pii: 12. [Epub ahead of print]10(1):
      
    Keywords:  Artificial intelligence; Gestational diabetes mellitus; Machine learning; Prognostic model; Risk prediction; Systematic review; Type 2 diabetes mellitus
    DOI:  https://doi.org/10.1186/s41512-026-00229-8
  2. J Diabetes Sci Technol. 2026 Apr 20. 19322968261441313
      
    Keywords:  diabetes; education; large language model
    DOI:  https://doi.org/10.1177/19322968261441313
  3. Diabetes Ther. 2026 Apr 21.
      The past year has continued the rapid evolution of diabetes technology across the monitoring, delivery, analytics, and patient-support domains. Improvements in continuous glucose monitoring (CGM) accuracy and wear-time options, widening use and regulatory expansion of automated insulin delivery (AID) systems, growth in connected insulin pens, maturation of digital therapeutics, and an influx of artificial intelligence (AI)-driven decision support tools have together shifted diabetes care toward tighter, more personalized, and more remote models of management. At the same time, device safety events, persistent affordability and access gaps, and data-interoperability and privacy challenges remind clinicians and policymakers that technology alone is not a panacea. This review summarizes the most important developments from last year (2025), highlights evidence from recent trials and regulatory actions, and discusses implications for practice and future directions.
    Keywords:  Artificial intelligence; Automated insulin delivery; Continuous glucose monitoring system; Diabetes technology; Digital therapeutics; Smart insulin pen
    DOI:  https://doi.org/10.1007/s13300-026-01871-7
  4. Clin Ophthalmol. 2026 ;20 586474
       Background: Retinal photographs offer great opportunity to early detect systemic disorders related to diabetes, including Chronic Kidney Disease (CKD).
    Purpose: To develop and validate a novel deep learning model to detect CKD among diabetic patients.
    Patients and Methods: We developed an EfficientNet-B2 Deep Learning (DL) model utilizing a weighted cross-entropy loss function to address class imbalance and distinguish retinal images among healthy controls, patients with isolated type 2 diabetes mellitus (T2DM), and patients with CKD stage 3 due to T2DM. The dataset was partitioned using a strict 80/20 patient-level split to evaluate bilateral eyes while strictly preventing data leakage. Model performance was evaluated using sensitivity, specificity, and area under the curve (AUC), alongside Grad-CAM visualizations for clinical interpretability.
    Results: The study included 225 participants. Among the evaluated DL architectures, the EfficientNet-B2 model demonstrated the best performance, achieving an overall AUC of 0.96. The model exhibited a sensitivity of 82%, specificity of 94%, precision of 81%, and an F1-score of 0.80. Class-specific AUCs were 0.99 for healthy controls, 0.90 for T2DM without CKD, and 0.90 for T2DM with CKD stage 3. Grad-CAM heatmaps indicated that the model primarily focused on the peripapillary and macular regions to make predictions.
    Conclusion: This study presents a three-class fundus-based DL model, trained with a weighted-loss strategy, to differentiate controls, isolated T2DM, and T2DM with CKD stage 3. Further external and prospective validation is needed before it can be considered for screening/triage use.
    Keywords:  artificial intelligence; chronic kidney disease; deep learning; retinal fundus photography; type 2 diabetes mellitus
    DOI:  https://doi.org/10.2147/OPTH.S586474
  5. JMIR Med Inform. 2026 Apr 21. 14 e87374
       Background: Digital twins (DTs) offer a paradigm for health care by enabling data-driven, simulation-capable representations of individual health trajectories. However, DT development remains limited by the scarcity of standardized, temporally structured, and multidomain data suitable for modeling chronic disease progression. Most existing DT studies rely on narrowly scoped or proprietary datasets, restricting generalizability. Public health datasets, such as the Midlife in the United States study, provide rich biopsychosocial information but are underused due to structural complexity and lack of semantic integration frameworks.
    Objective: This study aimed to develop and evaluate an ontology-guided, agent-orchestrated framework for constructing offline, simulation-capable, and progression-aware DTs from public health datasets. Using diabetes as a case study, the framework integrates agent-based orchestration, medical ontologies, and large language model (LLM)-assisted semantic reasoning with machine learning to support explainable feature structuring, risk prediction, and predictive "what-if" progression analysis.
    Methods: A 6-stage DT framework was developed and applied to Midlife in the United States wave 2 (baseline) and wave 3 (follow-up) data. Ontology- and LLM-assisted feature selection identified predictors across biological, behavioral, psychosocial, and socioeconomic domains. Cleaned and harmonized data were used to train predictive models (random forest, eXtreme gradient boosting, and logistic regression) to estimate diabetes onset at follow-up. A state-transition simulator was implemented to model between-wave progression dynamics, quantify transitions across low-, medium-, and high-risk states, and evaluate predictive "what-if" scenarios such as weight reduction and lifestyle improvement. Model performance was assessed using accuracy, F1 score, area under the receiver operating characteristic curve (AUC), and calibration metrics.
    Results: From 9976 candidate variables, ontology- and LLM-guided selection retained the top 200 relevant predictors spanning biological, behavioral, psychosocial, and socioeconomic domains. Predictive modeling achieved strong discrimination, with random forest (AUC=0.82, accuracy=0.76) and eXtreme gradient boosting (AUC=0.81, accuracy=0.75) outperforming logistic regression (AUC=0.78). The state-transition simulator reproduced realistic progression patterns: 33.9% (1414/4174) of participants changed risk states between waves, and the high-risk group increased from 10.8% (451/4174) to 32.2% (1344/4174). Next-state prediction accuracy reached 92.5%. Predictive "what-if" analyses showed that with a simulated 10% weight reduction, model-estimated diabetes cases decreased by 98 (from 576 to 478). A placebo test (0% weight change) produced less than 0.3% difference in risk distribution, confirming model stability.
    Conclusions: This study presents a foundational, ontology-guided, and agent-orchestrated framework for constructing offline, simulation-capable, and progression-aware DTs from public datasets. By combining semantic reasoning, multidomain predictors, and predictive "what-if" progression simulation, the framework transforms static population data into longitudinal, interpretable representations of individual health trajectories. The proof-of-concept application to diabetes demonstrates that public health data can support robust and explainable DT models for exploratory risk analysis and hypothesis generation, without implying causal intervention effects or direct clinical decision support.
    Keywords:   digital twin; MIDUS; Midlife in the United States; chronic disease; diabetes; large language models; multiagent AI; ontologies; public health datasets; risk prediction; simulation
    DOI:  https://doi.org/10.2196/87374
  6. Front Cardiovasc Med. 2026 ;13 1744588
       Aims: Type 2 diabetes mellitus (T2DM) is commonly observed in heart failure with preserved ejection fraction (HFpEF) patients. Despite its growing prevalence, HFpEF is frequently underdiagnosed. The aim of our study is to apply machine learning algorithms for identifying HFpEF in patients with T2DM.
    Methods: A total of 1,444 patients with T2DM who met the criteria were consecutively enrolled. Least absolute shrinkage and selection operator (LASSO) technique was applied for feature selection to identify key clinical variables. All patients were randomly divided into a training set and a test set at a ratio of 7:3. Extreme gradient boosting (XGBoost), random forest, K-nearest neighbors, support vector machine (SVM), light gradient boosting machine, decision tree and logistic regression were used to establish diagnostic models. The diagnostic performance of models was evaluated by the area under the receiver operating characteristic curve (AUC), precision, accuracy, F1 score, and Brier score. Calibration curve and decision curve analysis (DCA) were used to assess the accuracy and clinical validity of the model.
    Results: Patients were divided into HFpEF group and non-HFpEF group. XGBoost model (precision 0.812, accuracy 0.770, sensitivity 0.719, AUC 0.852, F1 score 0.741, Brier score 0.148) and SVM model (precision 0.784, accuracy 0.765, sensitivity 0.681, AUC 0.857, F1 score 0.745, Brier score 0.166) had the highest diagnostic performance. However, the calibration curve of the SVM model depart from the line of perfect calibration which confirmed poor calibration. Therefore, XGBoost was demonstrated to be best ML model in identifying HFpEF in patients with T2DM. Rankings of variable importance based on the Gain metric showed that B-type natriuretic peptide over 100 pg/mL had the highest importance score, followed by albumin, E/e', age and high-sensitivity cardiac troponin T.
    Conclusions: This study found XGBoost to be the optimal machine learning algorithm in identifying HFpEF in T2DM patients. Additionally, the model demonstrated substantial clinical utility, as assessed by DCA.
    Keywords:  XGBoost; diagnostic model; heart failure with preserved ejection fraction; machine learning; type 2 diabetes mellitus
    DOI:  https://doi.org/10.3389/fcvm.2026.1744588
  7. Funct Integr Genomics. 2026 Apr 21. pii: 85. [Epub ahead of print]26(1):
      
    Keywords:  Integrative genomics; Machine learning; Mitochondrial metabolism-related genes; Non-alcoholic fatty liver disease (NAFLD); Type 2 diabetes mellitus
    DOI:  https://doi.org/10.1007/s10142-026-01864-6
  8. Diabetes Res Clin Pract. 2026 Apr 21. pii: S0168-8227(26)00180-4. [Epub ahead of print] 113261
      This systematic review examines the application of Artificial Intelligence-Generated Content (AIGC) in developing virtual patients (VPs) for diabetes management. Through structured analysis of current literature, the study demonstrates how AIGC methodologies address key clinical challenges: generative adversarial networks create synthetic continuous glucose monitoring trajectories to overcome data scarcity; reinforcement learning optimizes personalized insulin regimens through simulated treatment responses; and multimodal fusion techniques generate detailed models for diabetic complications. These approaches demonstrate technical feasibility in retrospective analyses and experimental settings for medical education and clinical decision support. However, their translation to clinical practice awaits rigorous prospective validation with diabetes-specific endpoints. However, validation remains primarily retrospective, with limited prospective trials reporting diabetes-specific endpoints like time-in-range and hypoglycemia metrics. Critical implementation barriers include data privacy concerns, model generalizability across diabetes subtypes, and clinical workflow integration. An empirical mapping of included studies onto a three-dimensional maturity framework reveals that while 92% of studies achieve technical validation, none demonstrate implementation maturity and only one has prospective evidence of clinical efficacy. Future progress hinges on interdisciplinary collaboration to develop robust validation frameworks aligned with regulatory standards and to proactively mitigate algorithmic biases, thereby bridging the gap between technical innovation and dependable clinical application.
    Keywords:  Artificial intelligence generated content; Clinical decision support; Diabetes management; Generative adversarial networks; Medical education; Multimodal data fusion; Reinforcement learning; Virtual patients
    DOI:  https://doi.org/10.1016/j.diabres.2026.113261
  9. J Proteome Res. 2026 Apr 23.
      Type 2 diabetes (T2D), inflammatory bowel disease (IBD), and colorectal cancer (CRC) share overlapping metabolic alterations that hinder early, disease-specific diagnosis. Using publicly available serum metabolomics data sets (T2D: ST003390; IBD: ST003312; CRC: ST000284), a standardized workflow combining random forest-based imputation, log transformation, Pareto scaling, and ComBat batch correction was implemented prior to supervised machine learning. Eight algorithms (logistic regression, linear and RBF SVM, random forest, XGBoost, k-nearest neighbors, multilayer perceptron, and partial least-squares-discriminant analysis) were benchmarked for binary and multiclass classification using stratified 5-fold cross-validation, F1-scores, and bootstrapped ROC-AUC estimates. Binary models yielded near-perfect discrimination for T2D (AUC ≈ 1.0) and high accuracy for IBD and CRC (AUC 0.93-0.95), while multilayer perceptron and partial least-squares-discriminant analysis achieved multiclass accuracy >0.9 and macro-AUC 0.98. Mapping discriminative metabolites to KEGG pathways revealed disease-linked signatures, including glucose and lipid metabolism in T2D, amino acid and porphyrin metabolism in IBD, and nucleotide and sphingolipid metabolism in CRC, supporting proteome-metabolome network perturbations. The current comparative machine learning framework of serum metabolome demonstrates a robust, though variable, multidisease classification performance across conditions (T2D, IBD, and CRC) used in this study. This strategy has the potential to provide interpretable pathway-level markers that may inform future proteome- and metabolome-centered diagnostic strategies.
    Keywords:  Machine Learning; Metabolomics; Metabonomics; Multiclass Classification; Proteome-Metabolome Networks; Serum Biomarkers
    DOI:  https://doi.org/10.1021/acs.jproteome.5c01212
  10. Front Endocrinol (Lausanne). 2026 ;17 1722013
       Aims: This study aims to develop an interpretable machine learning (ML) model for predicting the occurrence of advanced diabetic kidney disease (DKD), with the objective of identifying patients at an early stage of the disease, thereby facilitating timely and appropriate clinical intervention.
    Methods: Variable selection was performed using a combination of the least absolute shrinkage and selection operator (LASSO) and recursive feature elimination (RFE) techniques. A prediction model was constructed and validated using eight ML algorithms, and the model's performance was evaluated using area under curve (AUC), accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), F1 score, Brier score, calibration curve, and decision curve analysis (DCA). The SHapley Additive exPlanation (SHAP) and partial dependence plot (PDP) methods were employed to interpret the model both locally and globally. Finally, the prediction model was integrated into a network platform based on the Shiny application for direct use by clinicians and patients.
    Results: Serum creatinine, age, hemoglobin, serum urea, serum ALP, serum UA, platelet count, serum osmolality, serum bicarbonate, and monocyte count were identified as the most important variables in the advanced DKD model. Eight ML models were developed using these five variables. Among them, the logistic regression (LR) model demonstrated accurate predictive ability in both internal and external validation, with AUCs of 0.948 (95%CI: 0.920-0.975) and 0.898 (95%CI: 0.883-0.913), respectively. Furthermore, the LR model exhibited excellent performance in terms of accuracy, sensitivity, PPV, NPV, F1 score, and Brier score. The results of the calibration curve and DCA also indicate a high degree of consistency between the predicted and observed risks of the RF model, with a net return approaching full coverage. The model developed is available through LR-based online calculators for clinicians, free of charge: https://dev2333.shinyapps.io/logistics1/.
    Conclusion: This study developed and validated an interpretable LR model for predicting the occurrence of advanced DKD. The LR model can assist clinical practice by effectively identifying individuals at higher risk of advanced DKD at an early stage, allowing patients to receive timely and personalized treatment, and thereby providing a reliable foundation for improving patient prognosis and optimizing medical resource utilization.
    Keywords:  SHapley Additive exPlanation; advanced diabetic kidney disease; explainable; machine learning; partial dependence plot; prediction model
    DOI:  https://doi.org/10.3389/fendo.2026.1722013
  11. Diabetes Obes Metab. 2026 Apr 22.
       OBJECTIVE: Diabetic macrovascular complications continue to drive substantial morbidity, yet early detection tools and deeper mechanistic understanding remain scarce. This study aimed to pinpoint circulating protein biomarkers for diabetic macrovascular complications while elucidating their biological significance.
    METHODS: We combined proteome-wide Mendelian randomization (MR), Cox proportional hazards regression, and proteome-wide association study (PWAS) to rank priority proteins. From these prioritized proteins, we constructed a machine learning-derived protein risk score. Functional enrichment, multi-omics integration, and longitudinal trajectory modeling were conducted, supplemented by phenome-wide MR analyses.
    RESULTS: A total of 43 proteins were identified, clustering in pathways associated with immune-inflammatory cascades and extracellular matrix remodeling. The resulting 12-protein panel achieved robust discrimination (AUC = 0.793), maintained reliable performance over a 15-year period, and delivered clear risk stratification. Multi-omics integration revealed synchronized links to cardiometabolic dysregulation and cardiac structural alterations. Longitudinal trajectory analyses demonstrated that protein perturbations emerged as early as 10-12 years prior to clinical onset. Phenome-wide MR uncovered pleiotropic associations across various disease categories and provided causal support for several prioritized proteins.
    CONCLUSION: This work identifies a robust circulating protein panel suitable for early forecasting of diabetic macrovascular events and sheds light on core biological drivers of disease progression. The findings underscore the value of integrating proteomics, time-series evaluation, and causal inference for biomarker discovery and mechanistic insight.
    Keywords:  Diabetic macrovascular complications; Machine learning; Mendelian randomization; Proteomics; Risk prediction
    DOI:  https://doi.org/10.1111/dom.70807
  12. Lancet Digit Health. 2026 Apr 22. pii: S2589-7500(25)00150-5. [Epub ahead of print] 100968
       BACKGROUND: Once considered a disease observed in older adults, type 2 diabetes is now increasingly seen in youth and adolescence. Young-onset (<40 years of age) type 2 diabetes progresses more rapidly than late-onset disease, but remains frequently underdiagnosed due to scarce screening and frequent misclassification. We aimed to develop a prediction model for young-onset type 2 diabetes to improve detection and reduce long-term health-care burden.
    METHODS: For this nationwide, retrospective cohort study, we constructed a deep learning-based prediction algorithm for young-onset type 2 diabetes driven by routine care data from both primary and secondary health-care sectors. We used this model to predict future risk at multiple time horizons spanning 0-24 months using data on previous hospital diagnoses, primary care prescriptions, and primary care health service events from nationwide Danish health registries.
    FINDINGS: The algorithm was trained on patient health trajectories from 3 435 638 individuals, of whom 16 828 developed young-onset type 2 diabetes between Jan 1, 1995, and Dec 31, 2018. The 0·1% highest-risk individuals had a relative risk of 118·1 (95% CI 113·1-122·5) compared with the general population when predicting type 2 diabetes debut 3-15 months after the date of assessment, with 0·23% (0·22-0·24) of cases detected at 5% positive predictive value threshold, and relative risk decreased to 74·6 (71·2-78·2) at 12-24 months. Using both primary and secondary care registries increased performance over models trained on data from single registries with the best single-registry model, achieving a relative risk of 97·2 (92·9-101·7) at 3-12 months to 50·0 (46·9-53·3) at 12-14 months. Cross-replication in each of the five Danish regions showed consistent performance and robustness to regional health-care differences. Model explainability revealed emphasis on both well established risk factors and other factors previously linked mainly to late-onset type 2 diabetes, with cardiovascular prescriptions proving to be a strong indicator of time to diabetes.
    INTERPRETATION: This study highlights the potential for using deep learning methods on longitudinal health data from both primary and secondary care to develop low-cost predictive tools for screening of young-onset type 2 diabetes.
    FUNDING: Novo Nordisk Foundation.
    DOI:  https://doi.org/10.1016/j.landig.2025.100968
  13. J Diabetes Investig. 2026 Apr 21.
       BACKGROUND: Obesity-induced left ventricular diastolic dysfunction (LVDD), associated with ectopic fat and dysfunctional epicardial adipose tissue (EAT), is emerging as a key research area due to its increasing prevalence and links to metabolic-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM). This underscores the importance of early risk assessment and intervention to prevent the progression of LVDD. We developed an interpretable machine learning (ML) model combining cardiac magnetic resonance (CMR) radiomics and clinical data to assess LVDD risk in MASLD/T2DM patients, enabling proactive treatment customization.
    METHODS: We prospectively analyzed 175 MASLD/T2DM patients, splitting them into training and external validation groups. After categorizing them as LVDD+ or LVDD-, we collected clinical data and extracted standardized CMR radiomics features to develop ML models. The optimal model was internally validated, interpreted using Shapley Additive Explanations (SHAP), and externally validated.
    RESULTS: LVDD prevalence was similar in both cohorts (45.5% vs 46.2%, χ2 = 0.108, P = 0.743) among 175 MASLD/T2DM patients. The extreme gradient boosting (XGBoost) model, combining CMR radiomics and clinical data, outperformed in both internal and external validations. SHAP analysis revealed five critical determinants of LVDD: three radiomics features from CMR images and two clinical variables.
    CONCLUSION: The XGBoost model, incorporating radiomics from CMR images and clinical data, outperformed other ML models in predicting LVDD risk in patients with T2DM and MASLD, enhancing risk assessment accuracy. This improvement allows for timely treatment adjustments, potentially preventing LVDD progression more effectively.
    Keywords:  Cardiac magnetic resonance; Left ventricular diastolic dysfunction; Radiomics
    DOI:  https://doi.org/10.1111/jdi.70315
  14. J Diabetes Complications. 2026 Apr 19. pii: S1056-8727(26)00075-9. [Epub ahead of print]40(6): 109330
       BACKGROUND: Vascular complications of Type 2 diabetes (T2D) significantly contribute to its morbidity and mortality. Identifying robust biomarkers is critical for improving risk prediction, understanding disease mechanisms, and guiding targeted therapies.
    METHOD: Fasting plasma samples from a subset of 542 participants in the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) trial were subjected to mass spectrometry. Participants were divided into groups for analysis based on presence of microvascular and/or macrovascular complications, and time of its occurrence (history of at baseline or during trial follow-up). Random Forest algorithm was applied to identify potential novel protein biomarkers. Gene ontology analysis was performed to determine the biological pathways and processes linked to these proteins.
    RESULTS: Fifty proteins associated with type 2 diabetes vascular complications were identified with 14 uniquely associated with microvascular complications, 13 with macrovascular and 23 common for both. Pathway analysis revealed seven main pathways underlying type 2 diabetes vascular complications including platelet degranulation and extracellular matrix interactions. Gene ontology analysis showed that these proteins functioned predominantly in the extracellular matrix and were involved in biological processes related to blood coagulation and lipoproteins remodelling.
    CONCLUSIONS: This study provides insights into the molecular mechanisms underlying type 2 diabetes vascular complications, highlighting novel protein biomarkers and their key biological pathways. These findings support the development of precision medicine strategies for risk prediction and targeted interventions in type 2 diabetes management. Further clinical validation of these biomarkers is warranted to confirm their potential utility in improving patient outcomes.
    Keywords:  Biomarkers; Machine learning; Molecular pathways; Proteomics; Type 2 diabetes; Vascular complications
    DOI:  https://doi.org/10.1016/j.jdiacomp.2026.109330
  15. Ren Fail. 2026 Dec;48(1): 2648313
      Hyperglycemia is a major risk factor for chronic kidney disease (CKD). This multicenter prospective study developed and validated a machine learning (ML) model to predict CKD risk in prediabetic and diabetic populations for early intervention, following TRIPOD+AI guidelines. Participants were enrolled from four communities, with three sites providing training (80%) and internal test (20%) datasets, and the fourth for external validation. Five ML algorithms were constructed, and SHapley Additive exPlanations (SHAP) was applied to interpret the optimal model. The XGBoost model showed excellent predictive performance, with AUCs of 0.905, 0.809, and 0.837 in training, internal test, and external validation sets, respectively. Serum creatinine (Scr), age, and hemoglobin (Hb) were the leading predictors, with higher Scr, older age, and lower Hb elevating CKD risk. Risk stratification (low: 0%-5%, medium: 5%-25%, high: 25%-100%) yielded distinct CKD incidences of 0.7%, 9.9%, and 55.5% (p < 0.001). An online prediction tool was further established for community screening. This validated ML model enables accurate risk prediction and stratification in hyperglycemic individuals, providing a feasible approach for early CKD detection and targeted prevention in community healthcare.
    Trial registration: Not applicable. The study is not a clinical trial.
    Keywords:  Hyperglycemia; SHAP; chronic kidney disease; community screening; machine learning; risk prediction
    DOI:  https://doi.org/10.1080/0886022X.2026.2648313
  16. Front Endocrinol (Lausanne). 2026 ;17 1810879
      [This corrects the article DOI: 10.3389/fendo.2025.1749805.].
    Keywords:  AI diagnostics; biomarkers; exocrine pancreatic insufficiency; pancreatogenic diabetes; precision medicine; reclassification; type 5 diabetes mellitus
    DOI:  https://doi.org/10.3389/fendo.2026.1810879
  17. Hum Factors. 2026 Apr 18. 187208261442810
      ObjectiveThis study proposes an AI-enhanced modular material selection approach for designing diabetic insoles. By customizing materials for forefoot and heel modules, the method enables personalized support and pressure redistribution, resulting in cost-effective insoles.BackgroundDiabetic foot ulcers occur as a result of elevated plantar pressure and poor foot sensation. To mitigate this risk, developing insoles that redistribute plantar pressure can significantly lower the likelihood of ulcer formation.MethodThe insole was fabricated using cost-effective silicone molding, with functional personalization achieved via an AI-enhanced approach that selected optimal, interchangeable cushioning materials for forefoot and heel modules of each patient. The design integrates a ¾-length porous silicone upper layer with regionally optimized materials. Laboratory wear trials involving 23 diabetic patients compared the offloading performance of the hybrid insole (AIO) against barefoot, a PORON® Medical 4708 insole (PUR), and a cork-EVA insole (EVA).ResultsAIO demonstrated a 37.6% reduction in peak plantar pressure compared to barefoot condition while increasing contact area by 36.0% across the plantar surface. It significantly outperformed the commercial insole (EVA) and matched a therapeutic insole (PUR) overall, with superior regional offloading at the heel.ConclusionThis study enhances diabetic foot care by combining efficiency of silicone molding with functionally personalized, modular design to achieve superior pressure redistribution. It establishes a paradigm of "modular personalization" for diabetic insoles, leveraging AI for patient-specific material selection within a standardized, biomechanically optimized geometry.ApplicationThe findings offer practical insights for clinicians and manufacturers seeking scalable, patient-specific solutions for preventing diabetic foot ulcers.
    Keywords:  AI-enhanced material selection; diabetes mellitus; diabetic insole; diabetic ulcer; patient-specific design; pressure offloading; silicone molding
    DOI:  https://doi.org/10.1177/00187208261442810
  18. Ibrain. 2026 ;12(1): 123-136
      Visual impairment has been recognized as a potential risk factor for depressive symptoms (DS) in diabetes patients, yet the role of visual function in predicting DS remains unexplored. This study aims to develop and validate a predictive model for DS risk in type 2 diabetes mellitus (T2DM) patients in community health settings, incorporating a visual function index (VF14). We conducted a cross-sectional study involving 542 T2DM patients from four community health centers in Guiyang. Univariate and multivariate logistic regressions identified significant predictors, while 10 machine learning algorithms were employed to construct the predictive model. Model performance was assessed using such metrics as receiver operating characteristic curves, accuracy, sensitivity, specificity, F1 score, Brier score, C-index, calibration curves, and decision curve analysis. A restricted cubic spline (RCS) analysis evaluated the score-dependent risk profiles between the VF14 and DS. Key predictors included body mass index (BMI), self-reported glycemic status, age-related macular degeneration, glycated hemoglobin (HbA1c), and VF14. Among the models, the gradient boosting machine exhibited the robust predictive performance, with an area under the curve of 0.73 and sensitivity of 0.72. The Shapley additive explanations analysis identified VF14, BMI, and HbA1c as the top risk factors. RCS analysis revealed a score-dependent risk profile between VF14 and DS risk. This study introduces a clinically interpretable tool for early DS risk stratification in T2DM patients, offering potential for improved risk assessment and timely intervention in community health settings.
    Keywords:  depressive disorder; early prediction; machine learning; type 2 diabetes mellitus; visual function index
    DOI:  https://doi.org/10.1002/ibra.70014
  19. J Cyst Fibros. 2026 Apr 23. pii: S1569-1993(26)00094-9. [Epub ahead of print]
       BACKGROUND: Cystic fibrosis related diabetes (CFRD) is a common complication in people with cystic fibrosis (PwCF), yet traditional diagnostic tools such as fasting glucose, HbA1c, and the oral glucose tolerance test (OGTT) often fail to detect early dysglycemia. Continuous glucose monitoring (CGM) generates high resolution glucose data, but analytic methods for extracting meaningful phenotypes remain limited.
    METHODS: CGM data from 82 PwCF aged 6 to 78 years were compared with 166 healthy controls (HC). Thirty-two glycemic features were extracted from 24-hour CGM segments. Uniform Manifold Approximation and Projection (UMAP) was trained using HC and CFRD data, and Silhouette scores quantified the alignment of each daily profile with these clusters. Group differences were evaluated using linear mixed effects models.
    RESULTS: UMAP showed complete separation between HC and CFRD. Mean Silhouette score values were +0.35 (95% CI: 0.31 to 0.38) for HC and -0.77 (95% CI: -0.83 to -0.71) for CFRD. PwCF classified as normal glucose tolerance (NGT) or impaired glucose tolerance (IGT) had negative Silhouette score values, -0.58 (95% CI: -0.67 to -0.49) and -0.56 (95% CI: -0.63 to -0.49), with no difference between groups.
    CONCLUSIONS: Machine learning analysis of CGM data revealed a pervasive dysglycemic phenotype in PwCF. NGT and IGT individuals showed similar glycemic profiles shifted toward the CFRD phenotype, indicating that OGTT categories underestimate early metabolic dysfunction. CGM based digital phenotyping offers a more sensitive and continuous assessment of dysglycemia and may improve early detection and risk stratification in PwCF.
    Keywords:  Continuous glucose monitoring; Cystic fibrosis; Cystic fibrosis related diabetes; Glucose dysglycemia; Machine learning
    DOI:  https://doi.org/10.1016/j.jcf.2026.04.001